OBJECTIVES-We sought to study exercise capacity at different points in time after left ventricular assist device (LVAD) implantation and subsequent heart transplantation (HTx). BACKGROUND-The lack of donor organs warrants alternatives for transplantation. METHODS-Repeat treadmill testing with respiratory gas analysis was performed in 15 men with a LVAD. Four groups of data are presented. In group A (n=10) the exercise capacities at 8 weeks and 12 weeks after LVAD implantation were compared. In group B (n=15), the data at 12 weeks are presented in more detail. In group C (n=9), sequential analysis of exercise capacity was performed 12 weeks after LVAD implantation and at 12 weeks and one year after HTx. In group D, exercise performance one year after HTx in patients with (n=10) and without (n=20) a previous assist device was compared. RESULTS-In group A, peak oxygen consumption (VO2) increased from 21.3±3.8 to 24.2±4.8 ml/kg/min (p<0.003), accompanied by a decrease in peak minute ventilation/carbon dioxide production (VE/VCO2 ) (39.4±10.1 to 36.3±8.2; p< 0.03). In group B Peak VO2 12 weeks after LVAD implantation was 23.0±4.4 ml/kg/min. In group C, levels of peak VO2 12 weeks after LVAD implantation and 12 weeks and one year after HTx were comparable (22.8±5.3, 24.6±3.3 and 26.2±3.8 ml/kg/min, respectively; p=NS). In group D, there appeared to be no difference in percent predicted peak VO2 in patients with or without previous LVAD (68±13 % vs. 74±15 %; p<0,37), although, because of the small numbers, the power of this comparison is limited (0,45 to detect a difference of 10%). CONCLUSION-Exercise capacity in patients with a LVAD increases over time; 12 weeks after LVAD implantation, VO2 is comparable to that at 12 weeks and one year after HTx. Previous LVAD implantation does not seem to adversely affect exercise capacity after HTx.
Introduction
Aging of the population and prevention of premature death from ischemic heart disease by improved medical and surgical management have led to a growing incidence of heart failure. Improved medical therapy for chronic heart failure has further reduced mortality, thereby expanding the number of patients with heart failure (1). Heart transplantation (HTx) is the ultimate treatment option for end-stage heart failure. However, due to a shortage of donor hearts, this therapy can be offered to only a very small number of patients. Therefore, mechanical circulatory support of the failing heart has been suggested as an alternative to HTx. To date, two types of internal left ventricular assist devices (LVADs) are available: the TCI HeartMate (Thermo Cardiosystems Inc., Woburn, Masschusetts) and the Novacor (World Heart Corporation, Ottawa, Canada), both mainly used as a bridge to transplantation. In selected patients the results are excellent with approximately 75 % successful bridging to transplantation and LVAD support time lasting up to three to four years (2, 3, 4) . Based on the growing experience with these devices, it seems realistic to use the LVAD as an alternative to HTx or long-term bridging (in terms of years) to transplantation in youngsters. One of the prerequisites for permanent or semi-permanent assisting is that exercise performance, although not normal, should be adequate for daily life activities, as is the case after HTx. Until now, few studies are available evaluating exercise capacity after LVAD implantation (5) (6) (7) (8) (9) (10) . Most studies are based on small numbers of patients from different institutions, with divergent postoperative care, rehabilitation programs and exercise testing protocols, which may limit direct comparison of the results. Only one study compares exercise performance in patients after LVAD implantation and following HTx (6) . Data on the ventilatory response to exercise and the progress of exercise performance after long-term LVAD implantation have not yet been reported. Therefore, we performed repeated exercise testing with respiratory gas analysis in a cohort of consecutive patients with end-stage heart failure with an assist device and after HTx. To find an effect of LVAD implantation on exercise performance after HTx, a comparison was made between a group of posttransplant patients with and without a previous LVAD.
Methods
Patients with a LVAD. Fifteen consecutive male patients (age 37±12 years [mean ± SD]) with refractory end-stage heart failure treated in our center with a pneumatic LVAD (TCI HeartMate) were included in the study (Table 1 ). All patients were in critical hemodynamic condition, with a mean ejection fraction of 13±5 %, cardiac output 3.2±0.5 l/min and a mean arterial pressure of 62±9 mm Hg, despite high doses of inotropic support and sometimes intra-aortic balloon counterpulsation. All patients were eligible as transplant candidates or were already on the waiting list. After LVAD implantation, patients could be mobilized at an early stage and participated in an intensive rehabilitation program supervised by a physical therapist, aimed at dynamic exercise, strength and endurance (see Appendix). 
Heart transplant patients.
A cohort of 20 consecutive male heart transplant recipients (mean age 52±10 years) without a previous HeartMate was used for comparison. All patients were in NYHA functional class I.
Study design.
Maximal exercise capacity 8 weeks after LVAD implantation was compared with that 12 weeks after implantation (Group A, n=10). All patients performed an exercise test 12 weeks after implantation (Group B, n=15).To support the hypothesis that exercise performance, with an assist device, is sufficient and comparable to that after HTx, we performed a sequential analysis of exercise capacity 12 weeks after LVAD implantation, as well as 12 weeks and one year after HTx in the same patients (Group C, n=9). Finally, exercise capacity one year after HTx in the post-LVAD group was compared to that in a cohort of transplant patients without a previous assist device (Group D).
Exercise studies.
All patients underwent treadmill exercise testing using a 2-min staged modified Naughton protocol or a modified Bruce protocol. Continuous breath-by-breath respiratory gas analysis (Oxycon, Jaeger inc, Breda, Netherlands) was performed. Measurements included heart rate, blood pressure, oxygen consumption (VO2), carbon dioxide production (VCO2), minute ventilation (VE) and respiratory exchange ratio (RQ=VCO2/VO2). Peak VO2 was defined as the average VO2 during the last minute of exercise and is expressed as ml/kg/min as well as ml/min. In addition, to correct for differences in age among the study groups, the percentage of the predicted values was calculated according to Jones (11, 12) . Oxygen consumption at the anaerobic threshold (AT) was identified as the oxygen uptake before the systematic increase in the ventilatory equivalent for oxygen (VE/VO2), without a concomitant increase in the ventilatory equivalent for carbon dioxide (VE/VCO2), together with the V-slope method (13, 14) . The ventilatory response to exercise was defined as VE/VCO2 at peak exercise (15) . All tests for patients with a LVAD were performed in the automatic mode of the device, allowing LVAD output to follow an increase of venous return.
Statistical analysis.
Data are presented as the mean ± SD. Statistical analysis was performed with two-tailed paired and unpaired Student t tests, as appropriate. For the sequential analysis of the three exercise tests in the same patients, repeated measures analysis of variance (ANOVA) was used. If relevant, 95% confidence intervals (CIs) of differences were calculated. A p-value < 0.05 was considered statistically significant. All analysis were performed using SPSS version 8.0 for Windows.
Results
All 15 patients with a LVAD completed exercise testing 12 weeks after implantation. In 10 of these patients, a test at eight weeks after implantation was available. There were two late deaths: one due to device failure 133 days after implantation and the other due to repeated cerebral embolism 432 days after implantation. Thirteen patients (87%) were successfully bridged to HTx after a mean duration of support of 181±125 days (range 71to 455 days). Early after HTx, three patients died: one patient died from peri-operative bleeding and two died from intractable infections. One patient was not fit to perform an exercise test 12 weeks after HTx due to pneumonia at that time. Thus, 9 patients completed exercise testing 12 weeks after LVAD implantation, as well as 12 weeks and one year after HTx (Fig.1) . Before LVAD implantation, all 15 patients were in NYHA functional class IV. After LVAD implantation, all patients demonstrated an impressive improvement in general well-being and complete recovery of organ function. Eventually, all cardiac medication could be stopped, even when previous right ventricular failure in the LVAD group was present. Only aspirin, 80 mg/day, was given to prevent thromboembolic complications. Group B:Exercise performance 12 weeks after LVAD implantation (Table 3) . Twelve weeks after LVAD implantation, all patients were in NYHA functional class I (apart from the limitations imposed by the drive lines and the console of the device). Peak VO2 averaged 23.0±4.4 ml/kg/min. (range 17.2 to 32.1), or 58±9% of the predicted value (range 43 to 80%), sufficient for normal activities of daily life (14) . There was no difference in peak VO2 between patients with ischemic heart disease (n=7) and those with dilated cardiomyopathy (n=8) (21.6± 2.6 vs. 24.2 ± 5.4 ml/kg/min). 
Group D:
Exercise capacity one year after HTx with and without a previous LVAD. Because of the large difference in the mean age between both groups, these data were only analyzed as percentage of predicted peak VO2. Without a previous assist device (n= 20), peak VO2 one year after HTx was 74±15% versus 68±13% of the predicted value in patients with a previous LVAD (n=10; p= 0,37 [NS]; 45% power to detect a difference of 10% with a twosided significance of 0,05). 
Discussion
The results of this study suggest that exercise performance after implantation of a TCI HeartMate LVAD in a group of patients with end-stage heart failure, who underwent intensive postoperative rehabilitation, is sufficient for activities of normal daily life. An increase in maximal exercise performance from 8 to 12 weeks could be demonstrated (Table 2 ), most likely due to postoperative convalescence and systematic strenuous training. One may speculate that longer assist times will result in an even better exercise performance. This improvement in exercise performance over time was accompanied by a significant decrease in the ventilatory response to exercise (VE/VCO2). This variable is often increased in patients with severe heart failure and is considered an independent and even better prognostic marker than reduced peak VO2 (15, 16) . Twelve weeks after implantation, peak VO2 averages 23.0 ml/kg/min, compatible with Weber class A (17) . Sequential analysis of exercise performance in nine patients at 12 weeks after LVAD implantation and then at 12 weeks and one year after HTx demonstrated similar peak VO2, AT and VE/VCO2 values. Therefore, apart from the limitations imposed by the operating console and the drive line of the HeartMate, activities with placement of a LVAD are expected to be comparable to those after HTx. Furthermore, exercise performance of patients one year after HTx with a previous LVAD approximates that of post-transplant patients without a previous LVAD. This indicates that the impact of pre-transplant LVAD, per se, implying a thoracotomy and laparotomy with a diaphragmatic incision through which the inlet conduit of the HeartMate is passed, together with the potential detrimental effects of cardiopulmonary bypass, does not appear to lead to late consequences in terms of diminished exercise capacity. However, the presence of a LVAD certainly complicates the transplant procedure and may lead to excessive bleeding. This may have contributed to the peri-operative death of one of the patients. In contrast, the excellent general condition before HTx, in all probability, is an advantage for post-transplant rehabilitation, although this could not be translated in terms of a shorter hospital stay after HTx.
Comparison with previous studies. Our results seem to diverge from those of other studies on this subject. In the Experience with left Ventricular Assist Device with Exercise (EVADE) trial (6), peak VO2 one to three months after LVAD implantation was reported to be 14.5±3.9 ml/kg/min, compared with 17.5 ±5.0 ml/kg/min after HTx. Mancini et al. (7)compared exercise performance in 20 patients with a LVAD with that of heart failure patients without mechanical support. Peak VO2 in the LVAD group was 16.0±3.8 ml/kg/min. Several factors may account for these differences. The EVADE study is a multicenter study comprising 18 patients. Because it was a multi-center study, postoperative care, rehabilitation and exercise testing may not have been identical. Exercise testing was performed earlier after implantation (51.9±20.4 days), when peak VO2 was not yet optimal (Table 2 ). Furthermore, the mean age and weight of our patients were considerably lower than those in EVADE (37±12 vs. 48±12 years, and 71±8 kg versus 76±12 kg, respectively), resulting in a higher predicted peak VO2 (39.6 vs. 33.6 ml/min/kg) and a higher normalized VO2 per kilogram. Most of the aforementioned differences from the EVADE study also apply to the study of Mancini et al. (7) . Furthermore, in that study, exercise testing was by way of a bicycle ergometer instead of a treadmill, as used in our study, which may render 10% to25% lower values of peak VO2 (18) . However, several small-scale studies in which exercise performance was measured by way of a treadmill demonstrated much lower peak VO2 values (12-17 ml/kg/min) than those found in our study (8) (9) (10) . Despite these differences in study design and patient characteristics, we believe that part of the excellent exercise performance of our patients with a LVAD is due to the intensive post-implantation training program.
Effect of training in heart failure. The influence of training on exercise capacity may be inferred from evidence showing that impaired exercise performance in patients with chronic heart failure is related not only to an impaired hemodynamic condition, but also to skeletal muscle abnormalities (19) (20) (21) like atrophy (22) , as well as alterations in muscle histology and biochemistry (23) . Sullivan et al. demonstrated, for the first time, that training could improve exercise capacity in patients with severe heart failure (24). Later, many other studies confirmed this, as reviewed by Piepoli et al. (25) . Several studies using muscle biopsies or nuclear magnetic resonance spectroscopy confirmed the improvement in muscle metabolism after training, independent of central hemodynamic changes (26) (27) (28) (29) . These data demonstrate that in patients with chronic heart failure, despite a limited cardiac output response, an intensive training program can improve exercise capacity significantly. After HeartMate implantation, total cardiac output will increase significantly, but pump flow is limited to approximately 10 liters/min. At rest, there is usually no contribution of the native heart; however, during exercise opening of the aortic valve has been observed, contributing to increased total blood flow. Based on a flow of 10 liters/min, a male patient should be able to reach a peak VO2 of approximately 1400 ml/min, if he has a normal hemoglobin and oxygen extraction. Because this value is similar to that found in our study, we assume that exercise performance was optimal for the given blood flow. From the onset of our LVAD program, our policy was aimed at the reversal of skeletal muscle abnormalities by implementation of an intensive training program guided by a physical therapist. The combination of an increase in cardiac output due to LVAD implantation and intensive post-implantation training likely resulted in optimal exercise capacity.
Study limitations.
Due to an inherent, considerable mortality and morbidity during the course of LVAD implantation and after successive HTx, only a limited number of patients was available for a complete longitudinal study of exercise performance (n=9, Group C). Therefore, additional analyses were performed on the larger data sets of patients at different time points after LVAD implantation (Group A, n=10) and one year after HTx with and without a previous LVAD (Group D, n=10 and n=20, respectively). The relatively young age of the patients with a LVAD limits the value of direct comparison of VO2 values with those of post-HTx patients without previous LVAD implantation. This can be partly overcome by using a percentage of individually predicted values. Furthermore, as in all small studies, an insignificant difference between two groups will have limited power. The patients in this study were relatively young, very motivated and male, which may have skewed the results and limited generalization to the whole population of patients with end-stage heart failure.
Conclusion. This study demonstrates that exercise performance in patients with severe heart failure treated with a TCI HeartMate LVAD, combined with an intensive rehabilitation program, increases over time and, at 12 weeks, is fully compatible with activities of normal daily life. Twelve weeks after implantation, exercise capacity is comparable to that at three months and one year after HTx. One year after HTx, there appears to be no difference in exercise performance between patients with and those without a previous LVAD as a bridge to transplantation. Therefore, with regard to exercise performance, a permanent LVAD holds promise as a potential alternative for HTx.
